Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Apr 10;37(11):855-857.
doi: 10.1200/JCO.19.00033. Epub 2019 Feb 27.

MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer

D Ross Camidge  1 , Kurtis D Davies  1
Affiliations
Editorial

MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer

D Ross Camidge et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Drilon A, Cappuzzo F, Ou SI, et al. Targeting MET in lung cancer: Will expectations finally be MET? J Thorac Oncol. 2017;12:15–26. - PMC - PubMed
    1. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19:2240–2247. - PMC - PubMed
    1. Piotrowska Z, Isozaki H, Lennerz JK, et al. Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion. Cancer Discov. 2018;8:1529–1539. - PMC - PubMed
    1. Ramalingam SS, Cheng Y, Zhou C, et al. Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA studyProceedings from the 2018 ESMO Congress, Munich, Germany, October 19-232018abstr LBA50
    1. Lai GGY, Lim TH, Lim J, et al. Clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor–mutated non–small-cell lung cancer. J Clin Oncol. 2019;37:876–884. - PubMed